Novo Nordisk seeks EU and U.S. approval for new diabetes treatment

Reuters
Lars Sorensen, CEO of Novo Nordisk, gestures during an interview at the company's headquarter in Bagsvaerd near Copenhagen, Denmark November 4, 2013. REUTERS/Fabian Bimmer/File Photo

OSLO (Reuters) - Danish Novo Nordisk said on Monday it has filed for the European Union and the U.S. approval of semaglutide to treat adults with type 2 diabetes. The company said the results of the clinical trial, which included more than 8,000 adults with type 2 diabetes, demonstrated statistically significant and sustained blood glucose control, and a statistically significant reduction of cardiovascular risk compared to placebo. (Reporting by Nerijus Adomaitis)